CHARACTERIZATION OF CROSS-TISSUE Mqtl EFFECTS AND THEIR RELEVANCE IN PSYCHIATRIC DISORDERS

Jingyu Liu,Dongdong Lin,Jiayu Chen,Nora Perrone-Bizzozero,Vince Calhoun,Juan Bustillo
DOI: https://doi.org/10.1016/j.euroneuro.2017.08.030
IF: 5.415
2019-01-01
European Neuropsychopharmacology
Abstract:Epigenetics has been known to mediate genetic risks and regulate gene expression in complex diseases. Due to substantial epigenetic variation, particularly DNA methylation, is tissue specific, sample accessibility has been one of the major road blockers in epigenetic research for human brain disorders. However, previous studies have shown that DNA methylation can also be significantly regulated by genetics and such effect is relatively consistent cross tissues. A better understanding of this genetic and epigenetic relationship can be very beneficial for the investigation of diseases pathology. In this work, we conducted a comprehensive analysis of genetic influence on DNA methylation across brain and peripheral tissues, characterized genetics and their target CpGs, and their functional relevance to psychiatric diseases. We performed a genome-wide methylation quantitative trait loci (meQTLs) analysis on postmortem brain prefrontal cortex, whole blood and saliva. Cis-acting SNP-methylation pairs (distance < 20k base pairs) were matched across tissues. The overlap of meQTLs and targeted CpG sites in different tissues were evaluated by a Fisher exact test. Cis-effect size among tissues was also compared. While focusing on cross tissue consistent SNP-methylation effects, enrichment tests were applied to explore the genomic distribution of targeted CpG sites, their annotation in functional pathways and diseases, and their enrichment in the CpG set with high brain-blood correspondence. In addition, we tested the enrichment of cross-tissue meQTLs in risk loci of five major psychiatric disorders reported by large-scale genome-wide association studies, and further explored their overlap with cross-tissue expression QTLs. Finally, we constructed cross-tissue consensus co-methylation networks for the meQTL targeted CpG sites. We found significant overlap of meQTLs and targeted CpGs cross tissue (34%-73%). MeQTLs in blood showed the strongest cis-effect followed by brain and saliva regardless of direction of effect. Cross-tissue meQTL targeted CpGs were highly distributed on CpG island shore regions (OR: odds ratio = 1.3, P = 2.8e-99) and had a much higher probability being blood brain correspondent than non-meQTL target CpGs (OR=6.6). Cross-tissue meQTLs showed significant enrichment in risk loci of five major psychiatric disorders (OR: odds ratio = [1.65 - 5.42]). In addition, these cross-tissue meQTLs also enriched significantly in cross-tissue eQTLs (OR = 16.21), where 351 SNPs were meQTl, eQTL, and carried significant schizophrenia risk, mainly from regions 6p21.1 – 6p24.3. Finally, we found more similar co-methylation network structure between brain and blood than brain and saliva, and identified one consensus module showing significant schizophrenia risk (Z= -4.54, p = 5.5e-6). Results show strong cross-tissue similarity of meQTLeffects, especially between brain and blood, and their significant enrichment in psychiatric disorders, supporting the surrogate role of peripheral tissues in studying pathology of genetic effect on brain disorders through methylation.
What problem does this paper attempt to address?